Summary & Overview
HCPCS J0281: Aminocaproic Acid Injection, 1 Gram
HCPCS Level II code J0281 denotes a 1-gram injection of aminocaproic acid, an antifibrinolytic agent used to reduce or prevent hemorrhage in a variety of clinical settings. Nationally, this code matters because it identifies administration of a medication often used in surgical bleeding control, trauma, and procedures with elevated bleeding risk, influencing billing, coverage determinations, and drug utilization monitoring.
Key payers covered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of reimbursement and coding context, payer coverage considerations, and the clinical settings where aminocaproic acid is commonly administered. The publication summarizes available benchmarks and common billing modifiers, notes typical sites of service, and outlines where further policy details or medical necessity language may apply.
This national-level brief is intended for coding professionals, billing managers, and clinical administrators seeking a clear, practical reference to HCPCS Level II code J0281 for use in claims processing and coverage review. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J0281 represents an injection of aminocaproic acid, 1 gram. The service is a parenteral hemostatic agent administration, typically provided when antifibrinolytic therapy is required to reduce bleeding.
Service Type: Injection / Parenteral Medication
Typical Site of Service: Hospital outpatient department, inpatient hospital setting, ambulatory surgical center, or other outpatient infusion/observation areas
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J0281 (Injection, aminocaproic acid, 1 gram) is an adult or pediatric patient with active bleeding or at high risk for bleeding where antifibrinolytic therapy is indicated. Common scenarios include perioperative management for cardiothoracic surgery, dental or minor surgical procedures in patients with hyperfibrinolysis, mucosal bleeding in hematology patients, or treatment of acute hemorrhage in trauma when tranexamic acid is contraindicated or not available. The clinical workflow begins with assessment of bleeding severity and indication for antifibrinolytic therapy by the attending physician. In an inpatient or outpatient infusion setting, nursing documents baseline vital signs, obtains informed consent as required by facility policy, and prepares the medication per institutional pharmacy protocol. A dose of J0281 is administered intravenously, typically diluted and delivered over a specified time based on local protocol and patient factors. Vital signs and bleeding status are monitored during and after administration. Medication administration, lot numbers, route, dose, and any immediate adverse reactions are documented in the medical record. Billing uses the HCPCS Level II code J0281 per gram administered, and appropriate modifier(s) are appended as indicated by payer and clinical circumstances.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|